Patent Term Extensions are here to stay … for now

Patent Term Extension (PTE) provisions in Australia have recently been the subject of an extensive review. The Government has recently announced, however, that it has no plans to release the Final Report. As previously reported (see Australia’s pharmaceutical patents under review and Australia’s pharmaceutical patents under review – submissions due by 21 January 2013) a

Differences in trans-Tasman patent law: extension of term for pharmaceuticals

This is the latest in a series of articles intended to highlight some of the major differences between the patent laws of Australia and New Zealand. Whereas patentees are typically encouraged to view Australia and New Zealand as a common market, the reality is that this impression may not be 100% accurate. As may be

A Kiwi-sized spanner in the works of the TPP?

We have previously reported on progress toward the Trans-Pacific Partnership (TPP) – a Free Trade Agreement (FTA) presently under negotiation by Australia, Brunei Darussalam, Chile, Canada, Malaysia, Mexico, New Zealand, Peru, Singapore, the United States, and Vietnam. Recently, the negotiating parties set themselves a goal of finalising the agreement by October 2013. The TPP will

Australia’s pharmaceutical patents under review – submissions due 21 January 2013

As previously reported, the Australian Government announced a review of the patent system as it relates to pharmaceuticals to establish whether it is “effectively balancing the objectives of securing timely access to competitively priced pharmaceuticals, fostering innovation and supporting employment in research and industry” and, in particular, whether the system “is being used to extend pharmaceutical monopolies at